To review clozapine's position in treatment algorithms for schizophrenia.
C lozapine was synthesized in 1958 and rapidly established itself as unique both clinically (for example, lack of EPS at therapeutic doses) and pharmacologically (for example, low affinity for the dopamine D 2 receptor). [1] [2] [3] Its profile challenged widely held notions at the time, including the integral relation between EPS and clinical response 3, 4 as well as the singular focus on dopamine, and particularly the D 2 receptor, in explaining antipsychotic activity. 5 It was first marketed in 1972 but within several years it was withdrawn from numerous countries because of a cluster of unexplained deaths, subsequently tied to an identified risk of agranulocytosis. 2 A seminal study carried out in the late 1980s established clozapine as superior to conventional antipsychotics in refractory schizophrenia, 6 paving the way for its reintroduction in the early 1990s, this time with the added requisite of routine hematologic monitoring. 2 At the same time, its unique clinical and pharmacological properties established it as the prototype of atypicality and set in motion the search for a new class of antipsychotics that might share its clinical benefits while circumventing its adverse effects, especially risk of agranulocytosis. The net result has been a steady flow of new antipsychotic drugs laying claim to success in this regard and, in fact, expanding the putative clinical benefits initially proposed for clozapine. 2, [7] [8] [9] Terms such as atypical, novel, and SGA have been used to distinguish this new group of medications from typical, conventional, or FGAs, and various explanations to explain the superiority of these newer medications have generated further distinctions within them as a class (for example, SGAs, compared with third-generation antipsychotics). 10, 11 Notwithstanding the confusion regarding terminology, 12, 13 for the purpose of discussions here, SGAs will be used as the descriptor for all newer antipsychotics.
SGAs: The Evidence
The SGAs rapidly supplanted their conventional counterparts as first-line treatment, 14, 15 driven in part by an assumption and scattered reports that these drugs at least paralleled clozapine's therapeutic superiority when compared with FGAs. 16, 17 The widespread use of SGAs has provided a rapidly growing body of evidence by which to assess them against the FGAs and clozapine itself. Most notably, the purported advantages of the SGAs, compared with FGAs, have been tempered, 18, 19 while clozapine has more clearly distinguished itself among other SGAs. Its superiority in partial and (or) nonresponsive schizophrenia has been firmly established, a finding that has been confirmed in efficacy trials 6, 20, 21 as well as in more recent large-scale effectiveness studies (CATIE and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study). 19, 22 Moreover, a recent meta-analysis demonstrated that clozapine produced a better response, compared with FGAs, with an effect size of D = 0.49, whereas other SGAs clustered around a 0.25 effect size (corresponding with 4 to 6 Positive and Negative Syndrome Scale points or 3 to 4 Brief Psychiatric Rating Scale points). 23
Clozapine: Current Status
It is ironic that while the SGAs quickly positioned themselves as a first-line treatment, this was not the case for clozapine. With its reintroduction, the FDA identified clozapine as a restricted medication with the requirement of regular hematologic monitoring, indicated for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatment. 24 This, in turn, was reflected in the American Psychiatric Association's clinical practice guidelines. 25 Here in Canada, Health Canada followed suit, although in this case the product monograph was even more restrictive, endorsing a trial of clozapine only following 2 failed antipsychotic trials. 26 This too was reflected in the guidelines of the Canadian Psychiatric Association 27 and the stipulation of 2 failed antipsychotic trials was embraced by other guidelines as well; for example, the National Institute for Health and Clinical Excellence in the United Kingdom 28 and the Royal Australian and New Zealand College of Psychiatrists. 29 As a result, clozapine has become a niche drug, a medication of last resort reserved for the most difficultto-treat (and discharge) patients with schizophrenia, often implemented when they are already many years into their illness. 30 In actual practice, it is both underprescribed and delayed in its use among treatment-resistant patients. Figures have suggested that clozapine is employed in only 20% to 50% of eligible patients. 31 More recently, a large effectiveness trial reported clozapine use in only 14% of potential candidates 32 ; Taylor et al 33 reported a mean duration of illness of 15.1 years before administration of clozapine; subjects were exposed to up to 13 antipsychotic trials, with 5 considered adequate in terms of dose and duration (mean 5.7; range 0 to 25). 33 Similarly, a recently published review of 847 charts noted clozapine was initiated 9.7 years after the onset of psychotic symptoms, with the range extending up to 43 years. 34 
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Clozapine, Agranulocytosis, and Mortality
At the time the FDA made its decision, available data indicated that clozapine-induced agranulocytosis occurred in about 1% of treated patients. 35, 36 Evaluation of the clozapine registry database in the United States (CPMS) 1 year after clozapine approval revealed a somewhat lower incidence (that is, 0.80% at 1 year and 0.91% at 1.5 years of treatment). 37 More recent data from the CNR in the United States report incidence of agranulocytosis to be even lower. Honigfeld et al 38 analyzed data from the CNR and identified only 382 cases of agranulocytosis (0.38%) in 99 502 clozapine-treated people. Data from other countries further support this diminished risk. In Canada, for example, the incidence of agranulocytosis between the years of 1991 to 1994 was reported to be as low as 0.65%, 39 while figures from Europe, Asia, and Australia indicated the risk of developing neutropenia and agranulocytosis to be about 3% and 0.8%, respectively. 40, 41 At the time of clozapine's reintroduction in the early 1990s, mortality rates owing to clozapine-induced agranulocytosis were estimated at 3% to 4% of identified cases. 42 Walker et al 43 linked data from the CNR to the US National Death Index and the US Social Security Administration Death Master Files to compare death rates in 99 502 current and former clozapine users. This study revealed only 12 deaths related to agranulocytosis (0.01%). A similar analysis of another database reported that deaths resulting from clozapine-induced agranulocytosis occurred in 0.03% of patients. 40 Subsequently, Munro et al 44 reviewed the cases of 12 760 subjects from this same database who were monitored by the CPMS between the years of 1990 to 1997. In this report, the cumulative incidence of neutropenia and agranulocytosis in clozapine-treated patients was 2.7% and 0.73%, respectively. Overall mortality (up to 1996) in this sample was 0.016%. 40, 44 It is also of note that the risk of developing agranulocytosis with clozapine falls to 0.08% after 1 year of treatment, with mortality rates decreasing accordingly. By this point, mortality rates are comparable with the risk of developing these side effects with other nonrestricted antipsychotics. For example, it has been reported that chlorpromazine's risk of agranulocytosis is 0.13%, 45 while a recent study estimated the risk for olanzapine in this regard to be 0.15%. 46, 47 In summary, clozapine registries and their associated compulsory blood monitoring systems (no blood, no drug) have established their effectiveness in reducing both the incidence of clozapine-induced agranulocytosis and associated mortality rates.
Balancing Risk and Clinical Evidence
Treatment algorithms routinely position clozapine as a third-line treatment, 48 but what are the chances of responding to a second antipsychotic other than clozapine when there is an inadequate response to a first antipsychotic trial? In fact, very few articles have investigated this question, and virtually all reports have examined switching in a more chronic population, where multiple trials may already have been undertaken. For the SGAs, uncontrolled studies have reported benefits in switching from one to another [49] [50] [51] ; however, these studies remain inconclusive and the benefit of such switches has been challenged. 52, 53 This was reaffirmed in a recent subanalysis of the CATIE, where switching antipsychotics in the case of partial response yielded no advantage, with the exception of clozapine. 52, 54 Our group recently described a standardized treatment algorithm adapted for the pharmacologic management of first-episode schizophrenia. 48 Patients progress along the algorithm according to clinical response, with poor responders receiving 2 SGAs before a trial of clozapine. Among 123 patients assessed at that time, 93 (76%) responded to the first trial of an SGA, while only 7 patients (23%) responded favourably to a second SGA trial. In contrast, in those nonresponders to a second SGA who agreed to a trial of clozapine, 10 (77%) responded ( Figure 1 ). These findings are in line with other evidence indicating that multiple trials of FGAs or SGAs offer modest chances of further improvement, compared with a switch to clozapine, 55 and raise the issue of whether clozapine would be better positioned as second-line treatment. 48 Implementation as soon as possible is certainly in line with the premise that early and effective treatment favourably alters outcome and can be associated with decreased suicide attempts, comorbid illness progression, repeated hospitalization, homelessness, and functional deterioration. 56, 57 This, of course, then begs the question as to whether clozapine should be the first-line treatment. At odds with this position are 2 studies failing to demonstrate its superiority, compared with FGAs when used in this fashion and followed over 1 year, 58 leading authors to speculate that the robust response established in antipsychotic-naive, first-episode psychosis produces a ceiling effect that minimizes treatment differences. 58
Other Considerations
Clinical Symptoms
In addition to clozapine's superiority in ameliorating treatment-resistant psychotic symptoms, it is notable for its indication for suicidal behaviour. The International Suicide Prevention Trial substantiated this for clozapine, compared with olanzapine, specifically, 59 while a more recent metaanalytic study indicated clozapine was associated with a 3-fold overall risk reduction in suicidal behaviour. 60 Reviews summarizing the effects of clozapine treatment on cognition suggest that some domains (for example, psychomotor speed, verbal fluency, verbal learning, and memory) may be improved with its use. 61 However, there is no evidence to indicate that clozapine is superior to other SGAs, and collectively the overall benefits of these drugs in this regard are modest at best, not of a magnitude that would translate to improved functional outcomes. 62 Along similar lines, clozapine is not unique among other SGAs in its claims of improved negative symptoms. That said, there remains a fundamental question as to whether these drugs (or, in fact, any medications to date) can substantially alter primary negative symptoms. 18
Side Effects
Clozapine and a limited number of SGAs, including quetiapine and aripiprazole, have a low liability for EPS that is also not dose-dependent. 63 This advantage is reflected in the fact that, despite clozapine's burden in terms of hematologic monitoring and other side effects, it is recommended for use in people whose primary diagnosis is a movement disorder, for example, Parkinson disease. 64 There is also speculation that clozapine may have an even lower risk of TD than at least some of the other SGAs. To the extent that EPSs have been associated with a risk of TD, 65 this may be true. However, while the SGAs as a class have been associated with lower rates of TD, 66 evidence is lacking to indicate that clozapine is superior on this dimension. It is possible that just as a ceiling effect (that is, treatment with relatively high doses of antipsychotics) minimizes treatment differences in first-episode psychosis, a floor effect (that is, treatment with relatively low doses of SGA) influences rates of TD with different atypicals, and makes it unlikely that distinctions can be statistically detected between the individual agents.
Conversely, clinicians familiar with clozapine will readily attest to the fact that limitations regarding clozapine use are not confined to hematologic concerns. As a class, the SGAs have been identified as bearing an increased liability for weight gain and related metabolic disturbances and clozapine, along with olanzapine, carry the greatest risk in this regard. 67 As an aside though, in a recent large epidemiologic study of about 67 000 patients, clozapine had the lowest risk of all-cause mortality, as well as death related to ischemic heart disease, when compared with both other SGAs and FGAs. 68 Sedation is a common side effect, as is sialorrhea, and clinicians must also be attentive to its association with myocarditis, respiratory compromise in combination with benzodiazepines, 69 and elevated risk of seizures at higher doses. 26
Response Trajectory, Adherence, and Time to Discontinuation
Evidence of a more rapid treatment effect with clozapine in first-episode schizophrenia has been identified. 58 Clozapine has also proven superior in terms of adherence among newly treated patients, as well as among outpatients with schizophrenia. A recent prospective cohort study using the National Central Registry in Finland, investigating 230 adults hospitalized with schizophrenia, found that patients treated with clozapine have a substantially lower risk of all-cause treatment discontinuation than patients treated with haloperidol. 70 These results are in line with results from Phase 2 of the CATIE trial. 71
Cost Effectiveness
A review of cost-effectiveness studies conducted in the United States, United Kingdom, Sweden, and Canada reveals that in treatment-resistant schizophrenia findings consistently favour clozapine over FGAs on measures of clinical efficacy, cost, and cost-effectiveness. This is despite its higher acquisition cost. 72 In a more recent cost-effectiveness analysis using published data from randomized controlled trials and epidemiologic studies, Wang et al 73 found that clozapine as a first-line, rather than a third-line, agent could lead to small gains in life expectancy and quality-adjusted life expectancy at the acceptable cost of US$24 100 per qualityadjusted life year.
An Argument for Earlier Clozapine Use
Clozapine's reintroduction in numerous countries through the early 1990s occurred in the context of compelling data regarding its clinical superiority, compared with FGAs, in refractory schizophrenia. 6 With a risk of agranulocytosis established, its use was yoked to the implementation of strict hematologic monitoring overseen by established registries. 2 Under these conditions, regulatory bodies and treatment guidelines positioned clozapine more or less as an antipsychotic of last resort, not to be used until suboptimal response and (or) intolerability to other agents had been demonstrated. Not surprisingly, this has substantially delayed and curtailed appropriate clozapine use. However, accumulating evidence on 3 separate fronts argue for a re-evaluation of the positioning of clozapine in treatment algorithms.
Safety
The implementation of mandatory hematologic monitoring has diminished the risk of agranulocytosis and associated mortality. 40, 74 Agranulocytosis is closely linked to the earliest stages of clozapine exposure, with risk decreasing rather than increasing over time. During the highest risk period, that is the first year, the incidence of agranulocytosis is less than 1% and declines thereafter. As treatment progresses this risk diminishes and begins to approach that for other antipsychotics (a risk that many clinicians may not even be aware of). 37, 39 The risk of both neutropenia and agranulocytopenia are influenced further by various individual factors, which include age, ethnocultural background, baseline white blood cell count and hemoglobin level, as well as dose. 44 While a one-size-fits-all strategy is the most expeditious approach to conveying relative risk, these data suggest that actual risk is more individualized and based on various factors.
Medicine provides other examples where the putative benefits of a drug have counterbalanced its identified added risks, with a decision of when to use the clinician's prerogative.
Quinidine represents one such instance, where earlier work clearly established its value in maintaining sinus rhythm after cardioversion from chronic atrial fibrillation. 75 Newer drugs are now available that have, to a large extent, supplanted quinidine use, but where to position it is left to the clinician's discretion despite evidence that quinidine carries a 3-fold risk of death compared with other Class 1 antiarrhythmics. 76 As an aside, increase in QT interval represents a strategy for monitoring quinidine's safety; however, unlike with clozapine's hematologic monitoring and the defined thresholds, there are no such imposed guidelines for electrocardiogram monitoring with quinidine.
More recent data that clozapine has the lowest all-cause mortality (including risk related to ischemic heart disease), in combination with evidence that it also is associated with the lowest mortality rate related to suicide, 68 has led to speculation that we may be doing our patients a disservice by setting up barriers to access. 68
Efficacy and Effectiveness
There is a growing body of evidence, including both efficacy and more recently effectiveness studies 17, 22, 55, 77 that collectively make a compelling case for clozapine's clinical superiority in treatment-resistant schizophrenia. [78] [79] [80] Clozapine has also demonstrated a unique role vis-à-vis suicidality 59, 60, 81, 82 that led to its FDA indication for patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behaviour. 83
Early Intervention
Accumulating evidence has highlighted the importance of early, effective treatment for schizophrenia and the negative consequences of delays. 84, 85 Treatment resistance may increase with successive relapses, 86 although it is evident in at least some people from the earliest stages of care. 48 Even with clozapine as a third-line agent, in an ideal world this could translate into effective treatment as early as 2 to 3 months after initiation of antipsychotic therapy in treatment-resistant populations, opening the door for effective early intervention.
Clozapine Circa 2009
Clozapine is by no means a panacea, burdened as it is by significant side effects and its own limited efficacy in refractory schizophrenia. However, among all other antipsychotics, it has proven unique. In light of the current evidence, we propose that clozapine be treated like other antipsychotics where the decision to use is weighed individually. We suggest that this simply represents best clinical practice and evidence-based medicine. In implementing treatment, our responsibility is to provide up-to-date information while the consumer, and caregivers as the case may be, have a right to be part of the decision-making process based on this evidence.
How might this play out with clozapine? As with other agents, its side effect profile will undoubtedly play a prominent role in discussions regarding choice, and risk of agranulocytosis and (or) need for monitoring will continue to deter its use for numerous potential candidates. These preconditions, in combination with lack of data supporting its superiority in the more responsive first episode population, make it an unlikely choice as first-line treatment. In truth, for many it may not even be considered a second-line option based on its side effects, need for monitoring, and existing clinical evidence (or lack thereof). For example, our own data suggest that about 1 in 4 people will demonstrate a response to a second SGA after failure on a first (Figure 1 ). 48 Without evidence that initiating clozapine at this point will increase the rate of response or improve longer-term outcome, it is likely that for many there is sufficient reason to try a second SGA other than clozapine. Conversely, the option is available to go to clozapine but with the caveat that data are as of yet lacking to substantiate its superiority at this point. It cannot be ignored though that a substantial number of the nonresponders at this stage are, in fact, refractory and at present we simply do not know if outcome can be enhanced through initiating clozapine at this point. It is hoped this gap in knowledge will stimulate trials that shed light on such issues. At the very least, we will garner information regarding the value of clozapine as a second-line treatment, although there is the potential to extend our understanding of refractory as we begin to isolate patterns of response earlier in the illness' course. While investigations of clozapine to date have offered valuable insights into its unique clinical effectiveness and side effect profile, there remain unanswered questions should we move toward a repositioning of clozapine in the treatment armamentarium for schizophrenia. For example, what is the efficacy of clozapine as a second-line agent for people with schizophrenia who have failed an adequate trial of a first-line antipsychotic agent? Randomized controlled trials are required to clarify this. Does earlier effective intervention at this second-stage of treatment alter functional outcomes for people, compared with later use of clozapine? This question takes on increasing importance as outcome measures shift their focus away from purely clinical domains and embrace a recovery-based model that is more multifaceted. Can we isolate markers that will allow clinicians to better identify people who will respond to clozapine or, conversely, be at risk of particular side effects. While such work is already in place, [87] [88] [89] [90] [91] its priority is underscored by clozapine's unique profile even among other SGAs.
In summary, we believe that the increasingly clear benefits of clozapine, balanced against its side effects and the gains that have been made in safety, argue against its restrictive use. In so doing, it is possible that we have not fully exploited the clinical benefits of this unique drug. With an illness such as schizophrenia, characterized as it is by limited clinical response and poor functional outcome, it behooves us to exploit all strategies that hold promise and at present this may not be the case with clozapine.
Résumé : Où positionner la clozapine : réexamen des données probantes
Objectif : Revoir la position de la clozapine dans les algorithmes de traitement de la schizophrénie.
Méthode : Le statut de la clozapine est revu dans le contexte de sa découverte initiale et de son profil clinique et (ou) pharmacologique unique, du sevrage et du lien avec des préoccupations hématologiques, de sa réintroduction avec des directives de surveillance, du prototype pour l'atypicalité, du positionnement dans les algorithmes de traitement, et des données probantes actuelles sur l'efficience, l'efficacité, et les effets secondaires.
Résultats : La surveillance hématologique mise en oeuvre lors de la réintroduction de la clozapine, ici en Amérique du Nord, s'est révélée apte à prévenir les décès liés à la clozapine secondaires à l'agranulocytose. Bien que ses autres effets secondaires soient aussi préoccupants, les données probantes actuelles ne lient pas la clozapine à des taux accrus de mortalité; en fait, elle semble faire mieux que d'autres antipsychotiques à cet égard. En outre, sa supériorité clinique comparée à tous les autres antipsychotiques a été confirmée tant par son efficience que par les essais sur l'efficacité.
Conclusions :
La schizophrénie demeure un défi thérapeutique, car de nombreuses personnes démontrent une réponse sous-optimale et un résultat fonctionnel médiocre. La clozapine est habituellement positionnée comme un traitement de troisième ligne de la schizophrénie, mais à la lumière des données probantes existantes, il est justifié de réexaminer les preuves.
